SciVision Biotech Inc (1786) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of SciVision Biotech Inc stock TWD 41.13, price TWD 51.10, that is 19.5% below the price, quality 53 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 37.23 TWD – 136.50 TWD · fair‑value band 22.73 TWD – 61.41 TWD · the 51.10 TWD price screens above the 41.13 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow SciVision Biotech in your weekly email
Every Wednesday you see whether SciVision Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products.
Show moreShow less
It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was founded in 1990 and is based in Kaohsiung, Taiwan.
Stock analysis
SciVision Biotech Inc (1786) currently trades at 51.10 TWD, while our model-based Fair Value estimate is 41.13 TWD, 20% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 52.25 TWD per share, and 6 of the 26 models we run sit above the 51.10 TWD price.
Bear case: the Asset-Based group reads lowest at 10.15 TWD, and 20 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 22.73 TWD (bear) to 61.41 TWD (bull), the price of 51.10 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SciVision Biotech Inc reported revenue of 887M TWD in FY2025 versus 506M TWD in FY2021, a compound +15.1%/yr. Reported net income was 162M TWD in FY2025, compounding +12.4%/yr from FY2021.
Key figures
Market cap 3.8B TWD (≈ $116M) Micro · P/E ratio 22.0 · P/S ratio 4.27 · EPS (TTM) 2.32 TWD · Dividend yield 3.7% · Net margin 20.0% · Return on equity 10.2% · Return on assets (EBIT) 8.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −20%, 1786 screens cheaper than that median.
Fair Value models
Bear22.73 TWDFair Value 41.13 TWDBull61.41 TWD
Price 51.10 TWD · Downside -19.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.3516 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic). Over 10 years: +12.8% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+9.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.5%
Dividend (yield on the price)3.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5.5% vs 9.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.35% → 21%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+55.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +52.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−19.5% · Below median
Profitability
Return on equity (12 months)10.2% · Above median
Return on assets6.1% · Above median
Net margin (12 months)20.0% · Top 25%
Operating margin (12 months)13.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.7% · Below median
Dividend yield (12 months)3.7% · Top 25%
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is SciVision Biotech Inc (1786) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 41.13 TWD versus a price of 51.10 TWD, about 20% lower (overvalued).
What is the fair value of 1786?
Our model-based fair value for SciVision Biotech Inc is 41.13 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 51.10 TWD.
What is the quality score of 1786?
SciVision Biotech Inc has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SciVision Biotech Inc (1786)?
Our model-based price target is the fair value of 41.13 TWD (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 22.73 TWD, optimistic scenario 61.41 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the SciVision Biotech Inc stock forecast for 2026?
Our models put fair value at 41.13 TWD, about 20% lower versus a price of 51.10 TWD (overvalued). Cautious scenario 22.73 TWD, optimistic scenario 61.41 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of SciVision Biotech Inc (1786)?
SciVision Biotech Inc reported trailing-twelve-month revenue of about 889M TWD (latest available figure, as of Nov 9, 2026).
Does SciVision Biotech Inc pay a dividend?
SciVision Biotech Inc currently shows a dividend yield of 3.74% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of SciVision Biotech Inc (1786) and when is the ex-dividend date?
SciVision Biotech Inc pays a dividend of 1.91 TWD per share a year, a dividend yield of 3.7%. The last ex-dividend date was Apr 29, 2026. The payout ratio is 82.3% of earnings. Free cash flow covers the dividend 0.16 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into SciVision Biotech Inc (1786)?
For today's price to be fair in a discounted-cash-flow model, SciVision Biotech Inc would have to grow free cash flow by +55.0 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.7 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 1786 use?
Our models discount SciVision Biotech Inc at 11.8 %: a base by market capitalisation (micro), damped by beta 0.48, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SciVision Biotech Inc that is +55.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has SciVision Biotech Inc (1786) delivered so far?
Over the past 5 years revenue at SciVision Biotech Inc grew +13.7 % a year. The price currently implies free-cash-flow growth of +55.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SciVision Biotech Inc (1786) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into SciVision Biotech Inc (+55.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SciVision Biotech Inc (1786)?
The free-cash-flow yield on the price is 0.59 %: that much free cash flow SciVision Biotech Inc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SciVision Biotech Inc (1786)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SciVision Biotech Inc it is 41.13 TWD per share (as of Nov 9, 2026), against a price of 51.10 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is SciVision Biotech Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 1786 trades above its calculated fair value: price 51.10 TWD, fair value 41.13 TWD, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1786?
No. The price is what the market pays today (51.10 TWD); the fair value is what the company's own numbers justify (41.13 TWD). For SciVision Biotech Inc the two are 9.97 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is SciVision Biotech Inc worth?
The market values SciVision Biotech Inc at about 3.8B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 51.10 TWD; our models calculate a fair value of 41.13 TWD per share.
What do the bullish and bearish scenarios say about 1786?
Our models span a range for SciVision Biotech Inc: cautious scenario 22.73 TWD, base 41.13 TWD, optimistic 61.41 TWD per share (as of Nov 9, 2026, price 51.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1786?
SciVision Biotech Inc trades at a price-to-earnings ratio of 22.0 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 41.13 TWD is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings: 32.4. Other multiples: P/B 1.9, P/S 4.3, EV/EBITDA 14.9.
How solid is the balance sheet of SciVision Biotech Inc (1786)?
Balance-sheet figures for SciVision Biotech Inc (as of Nov 9, 2026): return on equity 10.2%, debt of 0.19 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 1786 from its 52-week high?
SciVision Biotech Inc trades at 51.10 TWD, about 39% below its 52-week high of 83.20 TWD and 31% above the low of 39.00 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 41.13 TWD is for.
Which stocks are comparable to SciVision Biotech Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SciVision Biotech Inc stock attractive at the current price?
The data as of Nov 9, 2026: price 51.10 TWD, calculated fair value 41.13 TWD (−20%), Quality Score 53/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1786 calculated?
We run SciVision Biotech Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 41.13 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. SciVision Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SciVision Biotech Inc (1786)?
The closing price on Nov 9, 2026 was 51.10 TWD. Our model-based fair value is 41.13 TWD, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SciVision Biotech Inc right now?
The model range is unusually wide (22.73 TWD to 61.41 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of SciVision Biotech Inc
How large is the market capitalisation of SciVision Biotech Inc (1786)?
The market capitalisation of SciVision Biotech Inc is 3.8B TWD (≈ $116M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SciVision Biotech Inc (1786)?
The price-to-sales ratio of SciVision Biotech Inc is 4.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SciVision Biotech Inc (1786)?
Earnings per share at SciVision Biotech Inc are 2.32 TWD (price ÷ EPS = P/E 22.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SciVision Biotech Inc (1786)?
The dividend yield of SciVision Biotech Inc is 3.7% (payout 82.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SciVision Biotech Inc (1786)?
The net margin of SciVision Biotech Inc is 20.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SciVision Biotech Inc (1786)?
The return on equity (ROE) of SciVision Biotech Inc is 10.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SciVision Biotech Inc (1786)?
On an EBIT basis the return on assets of SciVision Biotech Inc is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SciVision Biotech Inc (1786)?
The operating margin of SciVision Biotech Inc is 13.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SciVision Biotech Inc (1786)?
Revenue at SciVision Biotech Inc is growing +0.7% versus a year earlier (3y avg +16.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SciVision Biotech Inc (1786)?
Earnings per share at SciVision Biotech Inc are growing −62.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does SciVision Biotech Inc (1786) hold?
SciVision Biotech Inc holds more cash than debt, 361M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch SciVision Biotech Inc in the live analysis
One click puts SciVision Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026